Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAU-SED vs ALDOMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reserpine depletes catecholamines (norepinephrine, dopamine) from adrenergic nerve endings by binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing neurotransmitter storage and leading to depletion of catecholamines.
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
Mild to moderate hypertension,Management of psychotic disorders (off-label)
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
Initial: 0.5 mg orally once daily; maintenance: 0.1-0.25 mg orally once daily.
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
Terminal elimination half-life: 45-90 hours (average 60 hours); clinical context: requires 5-7 days to reach steady-state; prolonged half-life may lead to cumulative effects
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Extensively metabolized in the liver via ester hydrolysis; major metabolite is trimethoxybenzoic acid; not fully characterized in humans.
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Renal (60-70% as unchanged drug and metabolites); fecal (20-30% via biliary elimination)
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
96% bound, primarily to albumin and alpha-1-acid glycoprotein
~10-20% bound to plasma proteins (primarily albumin).
8-10 L/kg; clinical meaning: extensive tissue distribution, high affinity for adipose tissue and brain
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
Oral: 40-50% (first-pass metabolism); Intramuscular: 100% (complete absorption)
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-60 m L/min), reduce dose by 50%. No adjustment needed for Cr Cl >60 m L/min.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
Contraindicated in severe hepatic impairment (Child-Pugh Class C). For moderate impairment (Child-Pugh Class B), reduce dose by 50% and monitor for excessive sedation. No adjustment for mild (Child-Pugh Class A).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
Not recommended due to lack of safety and efficacy data. Avoid use in children.
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
Initiate with 0.1 mg orally once daily; titrate slowly based on response and tolerability. Monitor for orthostatic hypotension and sedation.
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
Reserpine may increase the risk of suicide; patients should be monitored for depression. It should not be used in patients with a history of mental depression.
None
May cause severe depression, especially in patients with psychiatric history; may cause bradycardia, electrolyte imbalance, and gastrointestinal effects; caution in patients with peptic ulcer disease or gallstones due to increased gastric acid secretion.
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
History of mental depression (especially suicidal tendencies), active peptic ulcer, ulcerative colitis, concurrent electroconvulsive therapy (ECT), hypersensitivity to reserpine or rauwolfia alkaloids.
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
Avoid tyramine-rich foods (aged cheese, cured meats, fermented products, soy sauce) as rauwolfia alkaloids can potentiate hypertensive crises. Limit caffeine intake. High-fiber diets may reduce absorption separate doses.
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
Reserpine crosses placenta. First trimester: Increased risk of congenital malformations (cardiac defects, CNS anomalies) in animal studies; human data limited but risk considered elevated. Second/third trimesters: Risk of neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion due to catecholamine depletion. Avoid use throughout pregnancy unless essential.
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
Reserpine is excreted into breast milk. M/P ratio not reported. Potential for infant effects: nasal congestion, bradycardia, hypotonia. Use is contraindicated due to possible severe adverse effects in the nursing infant.
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
Dose should be kept as low as possible. Due to increased plasma volume in pregnancy, monitor clinical response; no specific dose adjustment recommendations. Consider alternative antihypertensives with better safety profile.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
RAU-SED (rauwolfia serpentina) is an antihypertensive and antipsychotic alkaloid. Onset of action is slow (2-3 weeks) for hypertension. Monitor for bradycardia, nasal congestion, and depression. Do not use with MAOIs or electroconvulsive therapy. Taper to avoid withdrawal hypertension.
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
Take exactly as prescribed; do not stop suddenly as this may cause severe hypertension.,May cause drowsiness, dizziness, or nasal congestion; avoid driving if affected.,Report signs of depression, nightmares, or extrapyramidal symptoms (muscle stiffness, tremors).,Avoid alcohol and over-the-counter cold medications containing decongestants.,Rise slowly from sitting or lying to minimize postural hypotension.
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAU-SED vs ALDOMET, answered by our medical review team.
RAU-SED is a Antihypertensive that works by Reserpine depletes catecholamines (norepinephrine, dopamine) from adrenergic nerve endings by binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing neurotransmitter storage and leading to depletion of catecholamines.. ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAU-SED and ALDOMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAU-SED is: Initial: 0.5 mg orally once daily; maintenance: 0.1-0.25 mg orally once daily.. The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAU-SED and ALDOMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAU-SED is classified as Category C. Reserpine crosses placenta. First trimester: Increased risk of congenital malformations (cardiac defects, CNS anomalies) in animal studies; human data limited but risk considered e. ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.